iRadimed reports Q1 adjusted EPS 49c, consensus 44c

Reports Q1 revenue $21.98M, consensus $21.32M. “We are pleased to report a strong start to 2026, with first-quarter revenue of $22.0 million, a 13% increase over the same period last year. Our continued revenue growth, combined with disciplined expense management, drove operating income of $7.2 million – a 33% improvement over the first quarter of 2025 – and net income of $5.8 million, or $0.45 per diluted share, a 22% increase over the first quarter 2025.”